Drug intelligence / Profile preview

diacerein + curcuma longa

Development stage
Unknown
Lead developer
Goldline Pharmaceutical
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Lukin NXT is a marketed fixed-dose combination capsule containing diacerein (50 mg) and Curcuma longa (turmeric) extract (50 mg), developed by Goldline Pharmaceutical. It is indicated for the symptomatic treatment of osteoarthritis, particularly of the knee and hip. Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) that inhibits the synthesis and activity of interleukin-1 beta (IL-1β), a key pro-inflammatory cytokine involved in cartilage destruction. Curcuma longa (curcumin) provides complementary anti-inflammatory and antioxidant effects by inhibiting the NF-κB and COX-2 pathways. Together, these components work synergistically to reduce joint pain, swelling, and stiffness while improving joint mobility and slowing cartilage breakdown.

Brand names
Lukin NXTLukin-Nxt
Other names
diacerein + curcumin
02

Targets

IL1B (Interleukin-1 beta)NF-κBPTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on diacerein + curcuma longa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diacerein + curcuma longa.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call